Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Sells $185,460.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush sold 11,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $185,460.00. Following the completion of the transaction, the chief technology officer now directly owns 121,503 shares of the company’s stock, valued at approximately $2,048,540.58. The trade was a 8.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Centessa Pharmaceuticals Trading Down 2.9 %

CNTA stock traded down $0.49 during mid-day trading on Tuesday, reaching $16.41. 461,939 shares of the stock traded hands, compared to its average volume of 593,205. The stock’s fifty day moving average is $16.76 and its 200-day moving average is $15.22. The company has a market cap of $2.16 billion, a P/E ratio of -10.73 and a beta of 1.53. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 52-week low of $7.38 and a 52-week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. As a group, sell-side analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its position in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares during the period. Walleye Capital LLC purchased a new position in Centessa Pharmaceuticals during the third quarter valued at approximately $187,000. China Universal Asset Management Co. Ltd. increased its stake in Centessa Pharmaceuticals by 99.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after buying an additional 6,785 shares during the period. Finally, Harbour Capital Advisors LLC purchased a new stake in Centessa Pharmaceuticals in the 3rd quarter worth approximately $259,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Guggenheim upped their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. TD Cowen assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.